Compare FINV & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | DCTH |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 668.1M | 578.4M |
| IPO Year | 2017 | 2015 |
| Metric | FINV | DCTH |
|---|---|---|
| Price | $2.85 | $20.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $5.62 | ★ $28.60 |
| AVG Volume (30 Days) | ★ 788.1K | 653.4K |
| Earning Date | 11-25-2026 | 11-09-2026 |
| Dividend Yield | ★ 11.25% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $36.66 |
| Revenue Next Year | N/A | $20.12 |
| P/E Ratio | ★ $3.87 | $101.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.66 | $8.12 |
| 52 Week High | $6.39 | $22.51 |
| Indicator | FINV | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 72.77 |
| Support Level | N/A | $10.76 |
| Resistance Level | $3.06 | N/A |
| Average True Range (ATR) | 0.13 | 1.10 |
| MACD | 0.00 | 0.81 |
| Stochastic Oscillator | 48.62 | 79.30 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.